SCL Science

SCL Science Earnings Yield

The Earnings Yield of SCL Science (246960.KQ) as of Nov 18, 2026 is -5.32 %. In the previous year, Earnings Yield was -5.04 % — a change of 5.47% (lower).

Earnings Yield

-5.32 %

YoY

5.47%

Last updated:

Earnings Yield of SCL Science is 2025 -5.32 % . Earnings Yield of SCL Science was 2024 -5.04 % . It decreases by 5.47% lower compared to the previous year.

The SCL Science Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
-3.48 KRW
Jan 1, 2019
-5.39 KRW
Jan 1, 2020
-4.12 KRW
Jan 1, 2021
-6.80 KRW
Jan 1, 2022
-8.07 KRW
Jan 1, 2023
-6.79 KRW
Jan 1, 2024
-5.04 KRW
Jan 1, 2025
-5.32 KRW
The SCL Science Earnings Yield history
YEAREarnings YieldYoY
-5.32 %+5.47%
-5.04 %-25.79%
-6.79 %-15.83%
-8.07 %+18.74%
-6.80 %+65.03%
-4.12 %-23.60%
-5.39 %+54.95%
-3.48 %-14.53%
-4.07 %+287.23%
-1.05 %-83.87%
-6.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Earnings Yield of SCL Science is -5.32 % in 2025.

Earnings Yield of SCL Science changed from -5.04 % to -5.32 %, representing a 5.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield SCL Science since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's SCL Science with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — SCL Science

All Key Metrics — SCL Science